Proteon Therapeutics Inc (NASDAQ:PRTO) Director James E. Flynn bought 110,557 shares of the stock in a transaction dated Thursday, November 30th. The shares were acquired at an average price of $1.75 per share, with a total value of $193,474.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Proteon Therapeutics Inc (NASDAQ PRTO) remained flat at $$1.90 during trading hours on Monday. The stock had a trading volume of 36,443 shares, compared to its average volume of 109,594. Proteon Therapeutics Inc has a 1 year low of $1.10 and a 1 year high of $10.57.
Several brokerages have recently weighed in on PRTO. Cowen restated a “hold” rating on shares of Proteon Therapeutics in a research note on Tuesday, August 8th. Oppenheimer restated a “market perform” rating on shares of Proteon Therapeutics in a research note on Wednesday, August 16th. HC Wainwright set a $2.00 target price on Proteon Therapeutics and gave the company a “hold” rating in a research note on Wednesday, August 9th. Zacks Investment Research upgraded Proteon Therapeutics from a “hold” rating to a “strong-buy” rating and set a $2.50 target price for the company in a research note on Tuesday, October 17th. Finally, Robert W. Baird restated a “hold” rating and set a $2.00 target price on shares of Proteon Therapeutics in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a buy rating to the company. Proteon Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.16.
COPYRIGHT VIOLATION NOTICE: “Proteon Therapeutics Inc (PRTO) Director Acquires $193,474.75 in Stock” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://weekherald.com/2017/12/04/proteon-therapeutics-inc-prto-director-acquires-193474-75-in-stock.html.
About Proteon Therapeutics
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.